Julphar takes step into Bangladesh market with RAK Pharma acquisition

13 February 2015

Julphar, the largest Emirati pharmaceutical company, has acquired a majority stake in Bangladesh drugmaker RAK Pharmaceuticals for $9.5 million, marking its entry into the region and an expansion of its footprint in Asia.

RAK Pharmaceuticals was a subsidiary of RAK Ceramics and produces a variety of industry compliant tablets, capsules and syrups that meet the requirements of a regulated health care market. The company reported $5.7 million of sales in 2013, representing growth of 24% on the year before.

Julphar and RAK Pharmaceuticals have had a long term strategic alliance through a joint partnership around technology transfer and a commercial marketing agreement for advanced pharmaceutical products.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK